MEDIVIR AB – INTERIM REPORT, JANUARY – SEPTEMBER 2016

Financial summaryJuly – September 2016 · Net turnover totalled SEK 67.8 million (111.5 m), of which SEK 12.4 million (69.0 m) comprised royalties for simeprevir. · Revenues from Medivir’s own pharmaceutical sales totalled SEK 44.0 million (42.5 m), of which SEK 1.3 million (2.8 m) derived from sales of OLYSIO® and SEK 42.7 million (39.7 m) from sales of other pharmaceuticals. · The profit after tax was SEK -50.4 million (-10.5 m). · Basic and diluted earnings per share totalled SEK -1.87 (-0.39) and SEK -1.87 (-0.39), respectively. · The cash flow from operating activities